Abiopharma

🔍 Kutzman Thomas J Jr (Executive)

Company: reAlpha Tech Corp. (AIRE)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Acquired 47,938 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: A | equity_swap_involved: 0 | shares_owned_after: 100,798.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 15,121 shares of Common Stock (Direct)
  Date: 2026-08-01 | Code: J | equity_swap_involved: 0 | shares_owned_after: 115,919.00 | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Represents restricted stock units ("RSUs") granted to the reporting person on July 30, 2026, as compensation for services as an executive officer during the quarter ended June 30, 2026, under the issuer's 2022 Equity Incentive Plan, as amended (the "Plan"). Each RSU represents a contingent right to receive one share of common stock of the issuer. These RSUs will vest as follows: (i) 50% will vest on the date that is 12 months from the date of grant and (ii) the remaining 50% will vest in four equal quarterly installments over the 12-month period thereafter, subject to the continuous service of the reporting person on such vesting dates and compliance with the terms and conditions of the Plan. The number of RSUs awarded was based on the 10-day volume weighted average closing price of the issuer's common stock, as reported on The Nasdaq Stock Market LLC ("Nasdaq"), for the period ending on and including July 30, 2026, which was $1.4341.
• F2: Represents shares of common stock of the issuer that were issued to the reporting person in satisfaction of the second installment of the deferred merger consideration payable in connection with the issuer's acquisition of Prevu, Inc., under that certain Agreement and Plan of Merger, dated November 21, 2025 (the "Merger Agreement"). These shares of common stock represent the portion of the deferred merger consideration payable to the reporting person under the terms and provisions of the Merger Agreement. In accordance therewith, a price per share of $1.4466 was calculated based on the 10-day volume-weighted average price of the issuer's shares of common stock, as reported on the Nasdaq, for the period ending on and including July 31, 2026, which represents a total deferred merger consideration payment of approximately $21,874.04 to the reporting person.